As jurisdictions plan reopening while COVID-19 still presents a threat, antibody testing to see the extent of exposure and possible immunity will be critical, but studies can and have been found to be flawed, so it's important to get the testing right. Dr. Eva Harris, a public health professor specializing in infectious diseases and vaccinology, is co-leading an extensive study of the Bay Area's exposure to the virus over time. Noting that not all so-called seroprevalence studies are created equal, she says it's important to be clear about that when discussing the implications of different studies' findings. Her study will monitor how seroprevalence and the number of asymptomatic infections in the community respond to changes in COVID-19 mitigation strategies. "I think that it's really important that many places do seroprevalence studies -- I'm super supportive of that," she says. "I also think it's incredibly important that people understand the limitations" of individual studies, she adds. "The study design and the test used and the interpretation have to be transparent to the [scientific] community, and there has to be some way to communicate that to the public." Read more about her study at Berkeley's School of Public Health. Another story mentioning this study appeared in the San Francisco Chronicle.